BARR PHARMACEUTICALS INC
Form 8-K
November 06, 2008

**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D. C. 20549**
**FORM 8-K**
**CURRENT REPORT**
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**
**Date of report (Date of earliest event reported) November 6, 2008**
**BARR PHARMACEUTICALS, INC.**
(Exact name of registrant as specified in its charter)

| Delaware | 1-9860 | 42-1612474 |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

| 225 Summit Avenue, Montvale, NJ | 07645 |
|---|---|
| (Address of principal executive offices) | (Zip code) |

(201) 930-3300
(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2008, Barr Pharmaceuticals, Inc. (the Company ) issued a press release announcing results for the quarter ended September 30, 2008. A copy of the release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Item 2.02 and in Exhibit 99.1 below shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and Exchange Commission.

The Company will host a Conference Call at 9:00 AM Eastern time on Thursday, November 6, 2008 to discuss earnings results for the quarter ended September 30, 2008. The number to call from within the United States is: (800) 230-1059 and (612) 288-0337 Internationally. A replay of the conference call will be available from 11:00 AM Eastern time on November 6, 2008 through 11:59 PM Eastern time November 13, 2008, and can be accessed by dialing (800) 475-6701 in the United States or (320) 365-3844 Internationally and using the access code 961801.

The conference call will also be webcast live on the Internet. Investors and other interested parties may access the live webcast through the Investor Relations section, under Calendar of Events, on Barr s website at www.barrlabs.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

99.1 Barr Pharmaceuticals, Inc. November 6, 2008 earnings release.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BARR PHARMACEUTICALS, INC.**

Date: November 6, 2008

/s/ William T. McKee
William T. McKee
Executive Vice President and Chief
Financial Officer